Ways of medicinal prevention and treatment of doxorubicin-induced cardiomyopathy in oncological patients
Keywords:doxorubicin-induced cardiomyopathy, chemotherapy, malignant neoplasms, myocardial dysfunction and heart failure, drug side effects
The high incidence of malignant tumors is currently supported by the general ageing of the world population and unfavorable environmental factors. In 2018, 18.1 million new cases of cancer and 9.6 million deaths from them were registered in the world. At the same time, a significant increase in the life expectancy of these patients after the treatment noted over the past 20 years highlights the problem of side effects of the anticancer therapy. One of the most serious side effects is the development of doxorubicin-induced cardiomyopathy (DRIC). In all three distinct clinical forms (acute, early and late) DRIC can develop in 58 % of patients after using anticancer treatment regimens with the inclusion of doxorubicin. The review provides a detailed analysis of medicinal treatment regimens and preparations (ACE inhibitors, beta-blockers, statins, etc.) currently used, and evaluates their effectiveness and expected results. Currently, several therapeutic strategies have been proposed for the prevention and treatment of DRIC, each of them has certain positive results. At the same time, some therapeutic methods used in the clinic have some disadvantages.
Conclusions. The limitations of the results of DRIC prevention achieved by the existing therapeutic regimens, as well as the possibilities for their prediction, have been stated. The need for further research to improve the effectiveness of medicinal prevention and treatment of DRIC is emphasized.
Zhang, Y., Liu, J., Li, Y., Tan, N., Du, K., Zhao, H. et al. (2020). Protective Role of Enalapril in Anthracycline-Induced Cardiotoxicity: A Systematic Review. Front Pharmacol., 11, 788. doi: https://doi.org/10.3389/fphar.2020.00788.
Korzeniowska, K., Jankowski, J., Cieślewicz, A., Jabłecka, A. (2019). Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence. Therapeutics and Clinical Risk Management, 15, 1095–1110. doi: https://doi.org/10.2147/TCRM.S215857.
Chang, H-M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., Yeh, E. T. H. (2017). Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol., 70 (20), 2536–2551. doi: https://doi.org/10.1016/j.jacc.2017.09.1096.
Reichardt, P., Tabone, M. D., Mora, J., Morland, B., Joneset, R. L. (2018). Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology, 14 (25), 2663–2676. doi: https://doi.org/10.2217/fon-2018-0210.
Dziuba, V. O., Kuchmenko, O. B., Yakoviichuk, O. V. (2018). Biolohiia tvaryn, 20 (1), 28–39. doi: http://doi.org/10.15407/animbiol20.01.028.
Higgins, A. Y., O’Halloran, T. D., Chang, J. D. (2015). Chemotherapy-induced cardiomyopathy. Heart Fail Rev., 20 (6), 721–730. doi: https://doi.org/10.1007/s10741-015-9502-y.
Vasiuk Yu. A., Nesvetov, V. V., Shkolnik, Ye. L., Fursov, S. A., Shkolnik, L. D., Hendlin, H. E., Emelina, E. I. (2017). Kardiolohiia, 57 (4), 31–37. doi: https://doi.org/10.18087/cardio.2417.
Kim, H., Kang, H. J., Park, K. D., Koh, K.-N., Im, H. J., Seo, J. J. et al. (2019). Risk factor analysis for secondary malignancy in dexrazoxane-treated pediatric cancer patients. Cancer Res Treat., 51 (1), 357–367. doi: https://doi.org/10.4143/crt.2017.457.
Zamorano, J. L., Lancellotti, P., Muñoz, D. R., Aboyans, V., Asteggiano, R., Galderisi, M. et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatements and cardiovascular toxity of the European Society of Cardiology (ESC). Eurepean Heart Journal, 37 (36), 2768–2801. doi: https://doi.org/10.1093/eurheartj/ehw211.
Raj, S., Franco, V. I., Lipshultz, S. (2014). Anthracycline-induced cardiotoxicity: A review of patho-physiology, diagnosis, and treatment. Current Treatment Options in Cardiovascular Medicine, 16 (6), 315. doi: https://doi.org/10.1007/s11936-014-0315-4.
Varricchi, G., Ameri, P., Cadeddu, C., Ghigo, A., Madonna, R., Giancarlo, M. et al. (2018). Antineoplastic drug-induced cardiotoxicity: A redox perspective. Frontiers in Physiology, 9, 167. doi: https://doi.org/10.3389/fphys.2018.00167.
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., Marwick, T. H. (2012). Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol., 60 (23), 2384–2390. doi: https://doi.org/10.1016/j.jacc.2012.07.067.
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., Yellon, D. M. (2017). Antracycline chemotherapy and cardiotoxicity. Cardiovascular Drugs and Therapy, 31 (1), 63–75. doi: https://doi.org/10.1007/s10557-016-6711-0.
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N. et al. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol., 35 (8), 893–911. doi: https://doi.org/10.1200/JCO.2016.70.5400.
Gupta, V., Singh, S. K., Agrawal, V., Singh, T. B. (2018). Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer, 65 (11), e27308. doi: https://doi.org/10.1002/pbc.27308.
Janbabai, G., Nabati, M., Faghihinia, M., Azizi, S., Borhani, S., Yazdani, J. (2017). Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol., 17 (2), 130-139. doi: https://doi.org/10.1007/s12012-016-9365-z.
Cardinale, D., Ciceri, F., Latini, R., Franzosic, M. G., Sandrid, M. T., Civelli, M. et al. (2018). Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international CardioOncology society-one trial. Eur J Cancer, 94, 126–137. doi: https://doi.org/10.1016/j.ejca.2018.02.005.
Kheiri, B., Abdalla, A., Osman, M., Haykal, T., Chahine, A., Ahmed, S. et al. (2018). Meta-analysis of carvedilol for the prevention of anthracycline-induced cardiotoxicity. Am J Cardiol., 122 (11), 1959–1964. doi: https://doi.org/10.1016/j.amjcard.2018.08.039.
Bansal, N., Adams, M. J., Ganatra, S., Colan, S. D., Aggarwal, S., Steiner, R. et al. (2019). Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology, 5, 18. doi: https://doi.org/10.1186/s40959-019-0054-5.
Avila, M. S., Ayub-Ferreira, S. M., de Barros, M. R. et al. (2018). Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol., 71 (20), 2281–2290. doi: https://doi.org/10.1016/j.jacc.2018.02.049.
El-Shitany, N. A., Tolba, O. A., El-Shanshory ,M. R., El-Hawary, E. E. (2012). Protective effect of carvedilol on Adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail, 18 (8), 607–613. doi: https://doi.org/10.1016/j.cardfail.2012.06.416.
Kaya, M. G., Ozkan, M., Gunebakmaz, O., Akkaya, H., Kaya, E. G., Akpek, M. et al. (2013). Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol., 167 (5), 2306–2310. doi: https://doi.org/10.1016/j.ijcard.2012.06.023.
Gulati, G., Heck, S. L., Ree, A. H., Hoffmann, P., Schulz-Menger, J., Fagerland, M. W. et al. (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J., 37 (21), 1671–1680. doi: https://doi.org/10.1093/eurheartj/ehw022.
Blanter, J. B., Frishman, W. H. (2019). The preventive role of ace inhibitors/angiotensin-ii receptor blockers and beta-adrenergic blockers in anthracycline and trastuzumab-induced cardiotoxicity. Cardiol Rev., 27 (5), 256–259. doi: https://doi.org/10.1097/CRD.0000000000000252.
Nohria A. (2013). B-Adrenergic blocade for antracycline – and trastuzumab-induced cardiotoxity is prevention better than cure? Cire Heart Fail, 6 (3), 358–361. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.113.000267.
Bosch, X., Rovira, M., Sitges, M., Domènech, A., Ortiz-Pérez, J. T., de Caralt, T. M. (2013). Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial. J Am Coll Cardiol., 61 (23), 2355–2362. doi: https://doi.org/10.1016/j.jacc.2013.02.072.
Nakamae, H., Tsumura, K., Terada, Y., Nakane, T., Nakamae, M., Ohta, K. et al. (2005). Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 104 (11), 2492–2498. doi: https://doi.org/10.1002/cncr.21478.
Kalam, K., Marwick, T. H. (2013). Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer, 49 (13), 2900–2909. DOI: https://doi.org/10.1016/j.ejca.2013.04.030.
Liu, G., Liu, Y., Wang, R., Hou, T., Chen, C., Zheng, S., Dong, Z. (2016). Spironolactone attenuates doxorubicin-induced cardiotoxicity in rats. Cardiovasc Ther., 34 (4), 216–224. doi: https://doi.org/10.1111/1755-5922.12189.
Akpek, M., Ozdogru, I., Sahin, O., Inanc, M., Dogan, A., Yazici, C. et al. (2015). Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail, 17 (1), 81–89. doi: https://doi.org/10.1002/ejhf.196.
Lipshultz, S. E., Herman, E. H. (2018). Anthracycline cardiotoxicity: the importance of horizontally integrating pre-clinical and clinical research. Cardiovasc Res., 114 (2), 205–209. doi: https://doi.org/10.1093/cvr/cvx246.
Acar, Z., Kale, A., Turgut, M., Demircan, S., Durna, K., Demir, S., Meric, M., Agac, M. T. (2011). Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol., 58 (9), 988–989. doi: https://doi.org/10.1016/j.jacc.2011.05.025.
Bernstein, D. (2018). Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking? Circulation Research, 122 (2), 188–190. doi: https://doi.org/10.1161/CIRCRESAHA.117.312395.
Ganatra, S., Nohria, A., Shah, S., Groarke, J. D., Sharma, A., Venesy, D. et al. (2019). Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series. Cardio-Oncology, 5 (1). doi: https://doi.org/10.1186/s40959-019-0036-7.
van Dalen, E. C., Caron, H. N., Dickinson, H. O., Kremer, L. C. (2011). Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev., 6, CD003917. doi: https://doi.org/10.1002/14651858.CD003917.pub4.
Cappetta, D., Rossi, F., Piegari, E., Quaini, F., Berrino, L., Urbanek, K., De Angelis, A. (2018). Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res., 127, 4–14. doi: https://doi.org/10.1016/j.phrs.2017.03.016.
Delle Donne, M. G., Iannielli, A., Capozza, P., De Caterina, R., Marzilli, M. (2020). Cardioprotective effect of Trimetazidine in patients with early breast cancer receiving anthracycline-based chemotherapy. European Heart Journal, 41 (2), ehaa946.0880. doi: https://doi.org/10.1093/ehjci/ehaa946.0880.
Corradi, F., Paolini, L., De Caterina, R. (2014). Ranolazine in the prevention of anthracycline cardiotoxicity. Pharmacol Res., 79, 88–102. doi: https://doi.org/10.1016/j.phrs.2013.11.001.
Saganelidze, Kh. Z., Kavtaradze, N. N. (2018). Georgian medical news, 5 (278), 87-91.
Copyright (c) 2021 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).